These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Neumann R; Foster CS Retina; 1995; 15(3):201-12. PubMed ID: 7569347 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of systemic lupus erythematosus: myths, certainties and doubts]. Ruiz-Irastorza G; Danza A; Khamashta M Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892 [TBL] [Abstract][Full Text] [Related]
6. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Smith KG; Jones RB; Burns SM; Jayne DR Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528 [TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Walsh M; Jayne D Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693 [TBL] [Abstract][Full Text] [Related]
8. [CD20 antibody for the treatment of systemic autoimmune diseases]. Tanaka Y Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437 [No Abstract] [Full Text] [Related]
10. [Management of systemic lupus erythematosus]. Aringer M; Schneider M Internist (Berl); 2016 Nov; 57(11):1052-1059. PubMed ID: 27670650 [TBL] [Abstract][Full Text] [Related]
11. [Safety and efficacy of biologics directed against TNF-alpha and CD20 in the therapy of vasculitis and systemic lupus erythematosus]. Walker UA; Hasler P Ther Umsch; 2008 May; 65(5):303-10. PubMed ID: 18622936 [TBL] [Abstract][Full Text] [Related]
12. Current role of rituximab in systemic lupus erythematosus. Mok CC Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 3. Cyclophosphamide for systemic rheumatic diseases]. Kameda H Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2918-23. PubMed ID: 22175131 [No Abstract] [Full Text] [Related]
14. [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases]. Harboe E; Gøransson L; Wildhagen K; Omdal R Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1650-2. PubMed ID: 15976831 [TBL] [Abstract][Full Text] [Related]
15. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease. Yuan S; Ye Y; Chen D; Qiu Q; Zhan Z; Lian F; Li H; Liang L; Xu H; Yang X Semin Arthritis Rheum; 2014 Jun; 43(6):759-66. PubMed ID: 24332116 [TBL] [Abstract][Full Text] [Related]
18. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861 [TBL] [Abstract][Full Text] [Related]